Surgery and neoadjuvant therapy in locally advanced pancreatic cancer: an umbrella review of survival, resection outcomes, and cost-effectiveness.

ABSTRACT:

Background

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a poor prognosis, particularly for patients with locally advanced pancreatic cancer (LAPC). Neoadjuvant therapy (NAT) has emerged as a promising strategy to improve resectability and survival outcomes in LAPC. This umbrella review aimed to synthesize the available evidence on the effectiveness of NAT and surgical interventions in LAPC, focusing on resection and R0 resection rates and overall survival (OS).

Methods

This study was registered with PROSPERO (CRD42024565454). A comprehensive literature search was conducted in June 2024 across four databases. Studies reporting on NAT and/or surgery in LAPC were selected, and the methodological quality of each meta-analysis was assessed using the A

SUBMITTER: Zhao Y 

PROVIDER: S-EPMC12004333 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature